Results 1 to 10 of about 244,949 (162)
Future of anti-VEGF: biosimilars and biobetters [PDF]
International Journal of Retina and Vitreous, 2022 AbstractThe advent of Anti- VEGFs like Lucentis (Ranibizumab), Eylea (Aflibercept) and off-label Avastin (Bevacizumab) have radically improved visual outcomes in patients of neovascular Age Related Macular Degeneration (nARMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO).
Monika Kapur +2 more
openaire +3 more sources
Scientific Reports, 2021 We evaluated changes in the complement system resulting from anti-vascular endothelial growth factor (VEGF) in eyes with age-related choroidal neovascularization (CNV) including neovascular age-related macular degeneration, pachychoroid neovasculopathy ...
Keiichiro Tanaka +13 more
doaj +1 more source
Anti VEGF for post op CME- Boon or Bane!
TNOA Journal of Ophthalmic Science and Research, 2022 Cataract surgery has advanced in techniques and instrumentation over the years, but complications such as cystoid macular edema (CME) do occur even after uneventful surgery.
Roshni Mohan, M Arthi, S Balamurugan
doaj +1 more source
BMC Health Services Research, 2023 Background We determined the cost-effectiveness of the anti-vascular endothelial growth factor (VEGF) intravitreal injection versus panretinal photocoagulation (PRP) for patients with proliferative diabetic retinopathy (PDR) in South Korea.
Hyeon-Jeong Lee +5 more
doaj +1 more source
Anti-VEGF Therapies in the Clinic [PDF]
Cold Spring Harbor Perspectives in Medicine, 2012 The development and use of antiangiogenesis agents, particularly those targeting vascular endothelial growth factor (VEGF), has become an integral component of anticancer regimens for many tumor types. This review is intended to highlight some of the most important clinical successes and failures of anti-VEGF therapies, and where possible, to suggest ...
Kellen L, Meadows, Herbert I, Hurwitz
openaire +2 more sources
Scientific Reports, 2021 The vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) axis is an essential regulator of angiogenesis and important therapeutic target in cancer.
Tetsuo Mashima +9 more
doaj +1 more source
Frontiers in Oncology, 2021 BackgroundIn recent years, immune checkpoint inhibitors (ICIs) in combination with chemotherapy have increased survival in patients with advanced non-small cell lung cancer (NSCLC).
Keiko Tanimura +14 more
doaj +1 more source
Indian Journal of Ophthalmology, 2023 Intravitreal injection of anti- Vascular Endothelial Growth Factor (VEGF)is commonly used to treat patients with diabetic macular edema (DME). However, the injection alone requires high cost and compliance.
Parangeni M Lubis +2 more
doaj +1 more source
Refractive status and ocular characteristics of preschool children with retinopathy of prematurity after different treatments [PDF]
International Journal of OphthalmologyAIM: To compare the changes in preschool refractive status, ocular biological parameters, and higher-order aberrations in children with retinopathy of prematurity (ROP) after retinal laser photocoagulation or anti-vascular endothelial growth factor (anti-
Wu-Yang Jiang +5 more
doaj +1 more source
Anti-VEGF– and anti-VEGF receptor–induced vascular alteration in mouse healthy tissues [PDF]
Proceedings of the National Academy of Sciences, 2013 Systemic therapy with anti-VEGF drugs such as bevacizumab is widely used for treatment of human patients with various solid tumors. However, systemic impacts of such drugs in host healthy vasculatures remain poorly understood. Here, we show that, in mice, systemic delivery of an anti-VEGF or an anti–VEGF receptor (VEGFR)-2 neutralizing antibody caused ...
Y. Yang +9 more
openaire +2 more sources